67015-06-9

Basic information

• Product Name: N-HYDROXY-PENTANAMIDINE
• Synonyms: N-HYDROXY-PENTANAMIDINE
• CAS NO: 67015-06-9
• Molecular Formula: C₅H₁₂N₂O
• Molecular Weight: 116.16158
• Product Categories: pharmacetical
• Mol File: 67015-06-9.mol
• Article Data: 11

Chemical Properties

• Melting Point: 27 °C
• Boiling Point: 176.7±23.0 °C(Predicted)
• Appearance: /
• Density: 1.05±0.1 g/cm3(Predicted)
• PKA: 7.48±0.69(Predicted)
• CAS DataBase Reference: N-HYDROXY-PENTANAMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-HYDROXY-PENTANAMIDINE(67015-06-9)
• EPA Substance Registry System: N-HYDROXY-PENTANAMIDINE(67015-06-9)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• Hazardous Substances Data: 67015-06-9(Hazardous Substances Data)

Upstream product

• 110-59-8 pentanonitrile 

Downstream Products

• 150849-84-6 (S)-3-butyl-6-(2-phenylethyl)-4H-1,2,4-oxadiazin-5(6H)-one 
• 135436-93-0 2-(3-butyl-[1,2,4]oxadiazol-5-yl)-phenylamine 
• 175473-43-5 N-Hydroxy-N'-[2'-(1-trityl-1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-pentanamidine 
• 175473-37-7 3-Butyl-4-[2'-(1-trityl-1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-4H-[1,2,4]oxadiazol-5-one 
• 175473-51-5 5-[4'-(3-Butyl-[1,2,4]oxadiazol-5-ylsulfanylmethyl)-biphenyl-2-yl]-1-trityl-1H-tetrazole 
• 175473-44-6 4-Butyl-3-[2'-(1-trityl-1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-[1,2,3,5]oxathiadiazole 2-oxide 
• 150758-58-0 3-butyl-6-phenyl-4H-1,2,4-oxadiazin-5(6H)-one 
• 150694-32-9 3-butyl-6-phenylmethyl-4H-1,2,4-oxadiazin-5(6H)-one 
• 150694-17-0 4'-<(3-butyl-5,6-dihydro-6-methyl-5-oxo-4H-1,2,4-oxadiazin-4-yl)methyl><1,1'-biphenyl>-2-carboxylic acid 
• 150694-42-1 4'-<<3-butyl-5,6-dihydro-5-oxo-6-(2-phenylethyl)-4H-1,2,4-oxadiazin-4-yl>methyl><1,1'-biphenyl>-2-carbonitrile 
• 150694-33-0 4'-<<3-butyl-5,6-dihydro-5-oxo-6-(phenylmethyl)-4H-1,2,4-oxadiazin-4-yl>methyl><1,1'-biphenyl>-2-carboxylic acid t-butyl ester 

Relevant articles and documents

OXADIAZOLE COMPOUNDS

The present invention relates to a compound of formula (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein R1,R2,R3,L1,L2,L3,L4,L5 and n, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of metabolic disorders and/or neurodegenerative diseases, and/or protein misfolding disorders.

PYRAZOLO [1,5-ALPHA] PYRIMIDINYL DERIVATIVES USEFUL AS CORTICOTROPIN-RELEASING FACTOR (CRF) RECEPTOR ANTAGONISTS

CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals. The CRF receptor antagonists of this invention have the following structure: (I); and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R1, R2a, R2b, Y, Het, n, o, R6, Ar and R7 are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention relates to novel compounds of formula (I) wherein W, n, X and W’ are defined in the description; invention compounds are modulators of metabotropic glutamate receptors - subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.